GlassScriptPhysician profile
Manpreet Kaur
NPI 1528309226
$1,284.40
in general payments reported to CMS, 2019-2025
22 companies · $52.95 in 2025
The $52.95 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $387 · 2022: $436 · 2023: $228 · 2024: $180 · 2025: $52.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $173.18 | 2021-2024 | Ojjaara |
| Janssen Biotech, INC. | $151.11 | 2022-2023 | Erleada |
| Genzyme Corporation | $111.80 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $93.21 | 2021-2024 | |
| Beigene USA, INC. | $83.97 | 2022-2024 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $71.37 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.99 | 2022 | |
| Karyopharm Therapeutics INC. | $61.16 | 2021 | |
| Pfizer INC. | $55.98 | 2022-2024 | |
| Seagen INC. | $55.27 | 2021-2023 | Adcetris |
| Lilly USA, LLC | $53.42 | 2021-2022 | |
| Eisai INC. | $45.24 | 2021-2024 | |
| Ipsen Biopharmaceuticals, INC | $45.05 | 2021-2023 | Tazverik |
| Kite Pharma, INC. | $39.43 | 2022-2024 | Yescarta |
| Sobi, INC | $29.08 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $28.20 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.75 | 2025 | Relistor |
| Array Biopharma INC | $23.85 | 2023 | Mektovi, Lorbrena, Braftovi |
| Astrazeneca Pharmaceuticals LP | $21.16 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $19.67 | 2021 | |
| Daiichi Sankyo INC. | $18.26 | 2023 | Enhertu |
| Celgene Corporation | $14.25 | 2023 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manpreet Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.